在抗脂综合征的华法林和肝素监测
Prabal Mittal1,2, Zara Sayar1,2, Hannah Cohen1
1Department of Haematology, University College London Hospitals, London, United Kingdom.
Hematology. American Society of Hematology. Education Program
|December 7, 2024
概括
抗脂综合征 (APS) 管理需要谨慎使用抗凝剂. 华法林和肝素是关键的,但由于影响国际规范化比率 (INR) 准确性的相互作用,监测可能是复杂的.
科学领域:
- 血液学 血液学 血液学
- 免疫学 免疫学 免疫学
- 血栓形成研究研究
背景情况:
- 抗脂综合征 (APS) 是一种导致血栓形成和妊娠并发症的获得性疾病,与抗脂抗体 (aPL) 相关.
- 有效的抗凝药对于管理APS患者至关重要,涉及瓦法林或肝素 (LMWH,UFH) 等维生素K对抗剂 (VKA).
- 精确监测抗凝强度对于有效治疗和预防APS至关重要.
研究的目的:
- 在APS患者中审查华法林/VKA的使用.
- 讨论在APS中的静脉和护理点国际标准化比率 (INR) 监测.
- 探索低分子量肝素 (LMWH) 和未分离肝素 (UFH) 在APS中的作用和监测,包括耐火病例和怀孕.
主要方法:
- 文献综述侧重于抗脂综合征中抗凝策略.
- 分析国际规范化比率 (INR) 监测在华法林治疗的APS患者中的挑战.
- 在APS中检查肝素 (LMWH/UFH) 的使用和监测协议.
主要成果:
- 华法林/VKA是血栓性APS的标准,但因狼抗凝剂 (LA) 相互作用而影响INR准确性.
- 肝素 (LMWH/UFH) 在特定情况下使用,需要仔细监测.
- 对APS患者抗凝血监测的挑战需要对可用的方法有全面的了解.
结论:
- 在APS中最佳的抗凝血需要仔细考虑监测方法,因为潜在的干扰,特别是在华法林患者的INR.
- 肝素提供了替代品,并在特定的APS管理场景中至关重要,包括怀孕和抗凝固剂耐药性.
- 本次审查强调了APS中抗凝管理的复杂性,强调了需要量身定制的监测策略的必要性.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
616
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
616
Disorders of Hemostasis
707
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
707
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
468
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
468
Endocarditis II: Clinical features and Diagnostic Tests
1
Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
1
Endocarditis IV: Nursing Management
1
Infective endocarditis (IE) is a chronic infection of the heart's endocardium, primarily affecting the heart valves. A detailed nursing assessment for a patient with IE involves collecting subjective and objective data to ensure an accurate diagnosis and timely intervention.Subjective DataThe nurse gathers information about the patient's symptoms and complaints during the subjective assessment. Patients with infective endocarditis often report non-specific symptoms that can mimic other...
1
Clot Retraction and Fibrinolysis
4.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
4.0K


